ESR1 and breast cancer: ERα-positivity is a favorable prognostic factor for BC, nevertheless, ER+ BC patients tend to lose ERα-positivity as a result of temporal and spatial heterogeneity and can recur several years after the completion of adjuvant therapy (35, 72).